Innovation Leader, Diego Miralles, M.D., Joins Adaptive Biotech As President Of Adaptive Therapeutics

SEATTLE--(BUSINESS WIRE)--Adaptive Biotechnologies, the leader in next generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, announces the appointment of Diego Miralles, M.D., as President of Adaptive Therapeutics. Most recently Dr. Miralles was the Global Head, Johnson & Johnson Innovation, where he established the Johnson & Johnson Innovation Centers, JLABS, and Janssen Healthcare Innovation. Dr. Miralles will build the Therapeutics Division of Adaptive, and head the Company’s efforts to leverage its best-in-class platform for identifying T- and B-cell receptors for use in therapies that will directly impact patient outcomes. In addition, Dr. Miralles will provide both scientific and commercial guidance to the existing and future programs and partnerships that Adaptive is implementing.

“Diego has an extensive scientific and pharmaceutical background and a strong reputation in leading and developing innovative drugs and businesses”

“Diego has an extensive scientific and pharmaceutical background and a strong reputation in leading and developing innovative drugs and businesses,” said Chad Robins, President, Chief Executive Officer and Co-Founder of Adaptive Biotechnologies. “We are looking forward to his experienced insight and strong leadership as he builds clinically impactful therapeutic programs for Adaptive. I truly believe that Diego’s enthusiasm, scientific intellect, executive-level leadership, personal industry relationships and drug development experience will help propel Adaptive to the next level.”

“Adaptive’s ground-breaking technology has created a substantial opportunity in the broad immune-based therapeutics space,” said Dr. Miralles. “I am passionate about the potential to positively impact patient outcomes and I am excited about the biological possibilities that such a technology enables. I see this as a great chance to make a difference to patients with currently unaddressed medical needs.”

Dr. Miralles joined Johnson & Johnson in 2005 as VP of Clinical Development at Tibotec in Belgium where he was involved in the development and approval of PREZISTA^® and INTELENCE^®, among several other drugs in the portfolio. He was a world leader in HIV therapeutics. In 2008, he moved back to the U.S. to head the Janssen Research and Early Development unit in La Jolla, California. Under his leadership, the La Jolla site has become a center of the life sciences community in San Diego. Dr. Miralles also founded and launched the JLABS incubator in 2012 for start-up life science entrepreneurs, a model that has been replicated in six locations across North America, and was instrumental in developing and launching Johnson & Johnson’s Innovation center model in 2013.

Prior to Johnson & Johnson, Dr. Miralles held R&D positions at Trimeris and Triangle Pharmaceuticals and was an Assistant Professor at Duke University Medical Center, where he was a scientist and an Infectious Disease physician, with a focus on HIV. He is currently an Adjunct Professor in the Department of Pharmacology at the University of California San Diego. Dr. Miralles received his M.D. degree from the Universidad de Buenos Aires, Argentina, and completed his internal medicine residency at the Mayo Clinic, and was a fellow in Infectious Diseases at Cornell University-New York Hospital.

About Adaptive Therapeutics

Adaptive Therapeutics is a new division of Adaptive Biotechnologies focused on the application of the Company’s proprietary technologies to pair T- and B-cell receptor chains together at high throughput and to determine the antigen-specificity of these receptors for therapeutic discovery. Adaptive is exploring many potential therapeutic applications including adoptive cell therapy, passive immunization, novel target discovery, and antibody engineering.

About Adaptive Biotechnologies^®

Adaptive Biotechnologies is the pioneer and leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. Adaptive is bringing the accuracy and sensitivity of its immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive also translates immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care. For more information please visit adaptivebiotech.com.